JNJ Johnson & Johnson
- Official Name: JOHNSON & JOHNSON
- Headquarters: One Johnson & Johnson Plaza, NEW BRUNSWICK, NJ, 08933 US
- CEO: Joaquin Duato
- Website: jnj.com
- Key Investor: VANGUARD GROUP INC | 9.72%
- Dedicated Investor: ROBERT WOOD JOHNSON FOUNDATION | 87.12%
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-16 | 1 | Won by 4.341 TOTW | 4.824 - 0.483 | ||
| 2025-07-23 | 2 | Won by 4.924 | 5.366 - 0.442 | ||
| 2025-07-29 | 2R | Won by 3.641 | 2.329 - (1.312) | ||
| 2025-07-30 | 3 | Lost by 0.842 | (2.105) - (1.263) | ||
| 2025-08-06 | 4 | Won by 3.762 | 1.963 - (1.799) | ||
| 2025-08-07 | 1R | Won by 3.007 | 0.614 - (2.393) | ||
| 2025-08-12 | 3R | Lost by 2.389 | (0.453) - 1.936 | ||
| 2025-08-13 | 5 | Won by 0.847 | 2.590 - 1.743 | ||
| 2025-08-20 | 6 | Won by 3.910 | 2.416 - (1.494) | ||
| 2025-08-21 | 2R | Won by 1.794 | 1.364 - (0.430) | ||
| 2025-08-27 | 7 | Won by 2.957 | (1.309) - (4.266) | ||
| 2025-09-03 | 8 | Won by 5.750 | 0.712 - (5.038) | ||
| 2025-09-04 | 3R | Won by 0.099 | 0.456 - 0.357 | ||
| 2025-09-10 | 9 | Lost by 2.623 | (1.256) - 1.367 | ||
| 2025-09-11 | 4R | Lost by 0.212 | 1.572 - 1.784 | ||
| 2025-09-17 | 10 | Won by 5.920 | 0.860 - (5.060) | ||
| 2025-09-17 | 1R | Won by 0.065 | 0.400 - 0.335 | ||
| 2025-09-24 | 11 | Lost by 1.104 | (0.291) - 0.813 | ||
| 2025-10-01 | 12 | Won by 4.348 TOTW | 5.285 - 0.937 | ||
| 2025-10-01 | QF | Won by 2.833 | 0.333 - (2.500) | ||
| 2025-10-08 | 13 | Won by 3.686 | 1.933 - (1.753) | ||
| 2025-10-15 | 14 | Won by 1.620 | 0.750 - (0.870) | ||
| 2025-10-15 | SF | Won by 0.868 | 0.176 - (0.692) | ||
| 2025-10-22 | 15 | Won by 1.173 | 0.863 - (0.310) | ||
| 2025-10-22 | F | Lost by 2.165 | 0.547 - 2.712 |
Latest News
Should You Invest in This Dividend King on the Dip?
Looking beyond near-term headwinds paints a fairly bright picture of Johnson & Johnson’s outlook.
Procter & Gamble Has Raised Its Dividend for 70 Years. These 2 Stocks Share Its Advantage
Raising dividends through two recessions takes more than a good brand name. Three companies with streaks stretching back decades show exactly what sep...
AbbVie’s Dividend Keeps Climbing. Is It Still a Buy for Income Investors?
AbbVie's stock has surged nearly 29% this year, but a rising share price compresses the yield even as the dividend keeps growing. Before adding s...
When the Stock Market Gets Dangerous, These 6 Investments Have a History of Holding Up
These companies generate resilient revenues, which help make their stocks less volatile during market downturns.
Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy.
The guidance bump doesn't matter nearly as much as investors' response to the company's Q3 report suggests.
What Was Eli Lilly Telling You Before Its Stock Ran?
An investor who put $10,000 into Eli Lilly (LLY) stock on October 14, 2025 held about $15,500 by October 15, 2026. Placing that same sum in the S&...
3 Great Biotech Stocks To Watch In October 2026
High energy costs are pushing inflation concerns back into focus after crude oil moved above US$100, and that kind of pressure often pushes investors ...
Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Bristol-Myers trades at a significant valuation discount, but its higher leverage and patent risks contrast sharply with Johnson & Johnson's ...
When Amgen's Forecast And Chart Say The Same Thing, Pay Attention
Amgen (AMGN) raised its revenue forecast for fiscal 2026 on August 4. Since the market close before that release, the stock has gained 15.2%, outpacin...
Gilead’s HIV Prevention Business Just Topped $1 Billion A Quarter. What Comes Next?
Gilead Sciences (GILD) built its foundation on HIV treatment. Biktarvy alone accounted for $14.3 billion of the company's $29.4 billion in fiscal...
Is Amgen Stock Increasing Your Market Risk?
Investors holding shares of Amgen (AMGN), the $234 billion maker of drugs such as Repatha and Prolia, likely pair that position with broad exposure to...
Forget AI Stocks: Buy Med-Tech Stock ISRG Now for 40% Upside
Intuitive Surgical stock earns a Zacks Rank #2 (Buy) and looks poised for a potential technical breakout as it overtakes vital long-term levels headin...
Johnson & Johnson: 3 Key Takeaways for Long-Term Investors
MedTech growth stalled while pharma surged, leaving the company to bet on new product launches and a planned spin-off to restore momentum.
The Stocks That Will Get Investors Home Safe When Tech Cracks
When tech stocks crack, most investors discover too late that their portfolios were far more concentrated than they realized. Jim Cramer and others ar...
Wells Fargo Maintains Overweight on Johnson & Johnson, Raises Price Target to $287
Wells Fargo analyst Larry Biegelsen maintains Johnson & Johnson (NYSE:JNJ) with a Overweight and raises the price target from $275 to $287.
9 Of 11 Sectors Rise In Friday Trading As Cyclicals Lead
Nine of 11 sectors are higher in Friday’s regular session, with cyclical sectors holding the top three positions. The leaders are separated rather t...
Does Raised 2026 Outlook Change The Bull Case For Johnson & Johnson (JNJ)?
Johnson & Johnson reported third quarter 2026 sales of US$25,399 million and net income of US$210 million, raised its full year outlook, and affir...
Committee For Medicinal Products For Human Use Recommends Approval Of Indication Extension Of Johnson & Johnson's TALVEY To Treat Adults With Relapsed Or Refractory Multiple Myeloma
https://www.jnj.com/media-center/press-releases/chmp-recommends-approval-of-johnson-johnsons-talvey-talquetamab-plus-daratumumab-in-earlier-line-treat...
3 Companies Raising Guidance This Earnings Season
Raised guidance is always a welcome development for investors, reflecting improving business trends and management confidence in the outlook.
Is Medtronic Stock A Buy Now That Sales Growth Has Picked Up?
Investors considering Medtronic (MDT) stock face an immediate concern: the shares returned 1.9% over the past year, trailing the 17.3% gain for the S&...
How Has Merck's Story Changed?
Investors are pricing Merck (MRK) stock at 5.5 times sales, compared with 3.1 for the S&P 500. Shareholders paying that premium need to understand...
Is Boston Scientific Stock Riskier Than It Was A Year Ago?
Investors in Boston Scientific (BSX) hold stakes in a medical device maker that grew revenue 13.5% over the twelve months to June 2026. Yet the shares...
Discover which dow jones stocks are making waves on Thursday.
Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.
Procter & Gamble Has Raised Its Dividend for 70 Years. These 4 Stocks Also Reward Patience
A dividend that keeps growing beats a fat yield that gets cut, but only if the company can actually afford to keep raising it. These five blue chips c...
XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?
Xenon pauses enrollment in late-stage depression trials after unexpected side effects, while its epilepsy pipeline offers growth potential.
AngioDynamics: Progress Evident, But Volatility And Margin Concerns Persist
AngioDynamics, Inc. stock analysis: AlphaVac, Auryon, NanoKnife growth vs execution risk and margin swings. Click for this updated look at ANGO prospe...
Where Could Johnson & Johnson's Next Growth Come From?
Johnson & Johnson (JNJ) stock trades at 29.1 times its earnings over the past twelve months, compared with 22.7 for the S&P 500. Investors pay...
Alto Neuroscience: Doubts Around Depression Candidate Merit Downgrade To Hold
Alto Neuroscience, Inc. pivots to ALTO-207 for treatment-resistant depression; learn risks, catalysts, dilution, and outlook. Click for this ANRO stoc...
Morgan Stanley Maintains Overweight on Johnson & Johnson, Lowers Price Target to $292
Morgan Stanley analyst Terence Flynn maintains Johnson & Johnson (NYSE:JNJ) with a Overweight and lowers the price target from $294 to $292...
Cramer’s Stop Trading: Johnson & Johnson
Jim Cramer's gives his insight regarding this healthcare giant.
How Much Downside Is Left In Liquidia Stock?
Over the past month, shares of Liquidia (LQDA) have lost 59%, even as the S&P 500 gained 2.5%. Reuters reported that the stock dropped nearly 50% ...
What Could BSX Stock Be Worth In Three Years?
Boston Scientific (BSX) stock currently trades at 17.2 times earnings. This compares to an average multiple of 55.9 over the last twelve quarter-ends,...
Discover which dow jones stocks are making waves on Wednesday.
Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Wed...
Johnson & Johnson CFO taps internal investment for medtech growth
The pharma company is on track to reach $100 billion in recorded revenue despite “temporary” headwinds in its medtech segment, executives said.
Johnson & Johnson: Stop Paying A Premium For Disappointment - Strong Sell
JNJ Q3 2026 earnings look strong, but deeper analysis shows declining shareholder earnings. Click for more on JNJ stock.
Leerink Partners Maintains Outperform on Johnson & Johnson, Lowers Price Target to $272
Leerink Partners analyst David Risinger maintains Johnson & Johnson (NYSE:JNJ) with a Outperform and lowers the price target from $276 to $...
These dow jones stocks are moving in today's session
Curious about the top performers within the dow jones index in the middle of the day on Wednesday? Dive into the list of today's session's t...
GSK: Maintaining Strong Buy For LAI HIV Sales Growth And Further Oncology Expansion
GSK plc stock update: oncology pipeline momentum (MoâRez phase 1), Cabenuva HIV data, Q2 results and 2026 phase 3 plansâclick for this GSK u...
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?
Sanofi's upgraded 2026 outlook, Dupixent growth and attractive valuation give it an edge over AbbVie, despite pipeline setbacks and vaccine sales...
Johnson & Johnson's Enterprise Review Expected to Sharpen Outlook, Morgan Stanley Says
Johnson & Johnson's (JNJ) review of its enterprise business on Dec. 8 is expected to sharpen the com
Why Did J&J Stock Fall After Q3 Earnings Despite Raised Guidance?
J&J's shares fell 5.8% despite an earnings beat and raised guidance, as MedTech weakness, drug sales shortfalls and acquisition costs weighed...
How To Retire: Hope For 95, Prepare For 105
Want to retire on income? Learn how a dividend portfolio using preferred shares and baby bonds can boost yield on cost and preserve principal.
The 3-Bucket Income System Making $13,000/Month in Pure Dividends
Most investors chase the highest yield they can find, but that single decision quietly destroys the income they worked to build. A three-bucket approa...
Johnson and Johnson Stock Plunges 6% As Medical Device Sales Miss Wall Street Forecasts
Key Stats for Johnson and Johnson StockPrice change for Johnson and Johnson stock in the last 6 months: 4%$JNJ Stock Price as of Oct. 13: $24952-Week ...
Johnson & Johnson Q3 Sets 'Negative Tone For Broader Pharma Sector': Analysts
Johnson & Johnson posted upbeat Q3 results; analysts stayed bullish, though RBC cut its target and noted mixed product and MedTech trends.
J&J earnings set ‘negative tone’; Shkreli vs. the FTC
A 6% sell-off in J&J shares was viewed by one analyst as emblematic of broader market volatility. Elsewhere, Gilead is collaborating with Vir and ...
Kevin O’Leary Warns: ‘Do Not Invest in Your Brother’s Restaurant.’ Here Are His 3 Rules for Retirement Money
Kevin O'Leary's retirement playbook starts with a warning that catches most people off guard, and it has nothing to do with stocks or bonds....
These Analysts Cut Their Forecasts On Johnson & Johnson After Q3 Results
Johnson & Johnson beat Q3 estimates and raised full-year guidance; sales rose 5.9%, EPS fell 7.5%. Analysts trimmed price targets.
The Open Question Under Johnson & Johnson Stock's Price
Johnson & Johnson (JNJ) has introduced several new drugs recently, and current buyers of its stock may be betting on their commercial success. The...
J&J Beat and Raised. The Stock Fell Anyway. Here’s What the Target Says
Johnson and Johnson crushed earnings, raised guidance, and still watched its stock crater nearly 6% in a single session. Understanding what spooked in...
Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying
Every big pharma company eventually watches its best-selling drug go generic, yet some keep raising their dividends anyway. The five names on this lis...
JNJ Q3 Earnings Call Highlights Growth Outlook and MedTech Challenges
Johnson & Johnson raises its 2026 sales and earnings outlook as strong pharmaceutical growth offsets MedTech challenges, while 2027 dilution cloud...
Wells Fargo Maintains Overweight on Johnson & Johnson, Lowers Price Target to $275
Wells Fargo analyst Larry Biegelsen maintains Johnson & Johnson (NYSE:JNJ) with a Overweight and lowers the price target from $282 to $275.
Stock Market Today: Big Banks Earn Billions, Bumble Soars on Buyout
JPMorgan, Goldman, Citi and Wells Fargo earned nearly $32 billion but trading desks sent mixed signals. Bumble jumped 57% on a buyout; ASML beat this ...
What the interest rate danger zone means for your money
Gabelli Funds Portfolio Manager Justin Bergner and NYSE Senior Market Strategist Michael Reinking break down how the AI boom, rising interest rates, a...
RBC Capital Maintains Outperform on Johnson & Johnson, Lowers Price Target to $280
RBC Capital analyst Trung Huynh maintains Johnson & Johnson (NYSE:JNJ) with a Outperform and lowers the price target from $290 to $280.
Stock of the Day: Is this the Bottom for Johnson & Johnson?
Johnson & Johnson found support near $246 after an earnings drop, with buy orders potentially signaling a bottom and rally.
SLS, IBRX Rise Premarket: Funds Raise Their Bets As J&J Stays ‘On The Lookout’ For Deals
J&J is open to strategic acquisitions and targets more than $50 billion in oncology sales by 2030.
Dow Jones Industrial Average Monitor Update - A Look At 30 U.S. Large-Caps
Visible Alpha consensus expects the Dow Jones Industrial Average to deliver an 18.7% weighted price return in the medium term. Read more here.
J&J Selloff Exposes Medtech Strain: Is Pharma Carrying Healthcare Stocks?
The J&J selloff shows how medtech weakness can outweigh pharma strength, and what it means for healthcare stocks.
J&J (JNJ) Q3 2026 Earnings Call Transcript
Innovative Medicine drove 7.9% growth as revenue hit $25.4 billion.
Review & Preview: Not a Bang but a Whimper
Investors were unimpressed with solid results from big banks. Wall Street is in a pessimistic mood. That may not be a bad thing.
Is Amgen Stock Worth More Than Its Competitors?
Amgen (AMGN) competes in a tight peer group of six large drugmakers alongside AbbVie, Johnson & Johnson, Merck, Pfizer, and Bristol-Myers Squibb. ...
UnitedHealth vs. Johnson & Johnson: Which Stock Is the Better Buy After Q3 Earnings?
Healthcare giants UnitedHealth Group and Johnson & Johnson reported Q3 results on Tuesday, with both raising their full-year earnings outlooks but...
Retiring at 56 on $5,950 a Month for Life: The Portfolio Size Most People Guess Wrong
Most people reach for the 4% rule when they picture retiring at 56 on nearly $6,000 a month, but that rule answers a completely different question tha...
Bank of America, Johnson & Johnson, Six Flags Entertainment, Citigroup and Applied Materials: Why These 5 Stocks Are on Investors' Radars Today
BAC, JNJ, FUN, C, AMAT were among the stocks seen trending among investors on Tuesday, Oct. 13, 2026.
Stock Market Today, Oct. 13: Markets Edge Lower as Earnings Season Kicks Off
Healthcare and semiconductor stocks led declines as investors digested mixed corporate results and competitive pressures, today, Oct. 13, 2026.
Stocks Struggle Ahead of September CPI Report: Stock Market Today
Stocks closed lower Tuesday as earnings season started with a whimper. Will tomorrow's inflation data provide a positive catalyst?
What Does Bristol-Myers Squibb Offer That Pfizer Does Not?
Pfizer (PFE) and Bristol-Myers Squibb (BMY) are bought for the same underlying reason: the search for new drugs to replace older ones losing market ex...
Sector Update: Healthcare Stocks Fall Late Afternoon
Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index and the State St
What Is Eli Lilly Stock's Biggest Opportunity?
Investors are currently valuing Eli Lilly (LLY) stock at a premium, with shares priced at 39.5 times earnings compared with 21.9 for the S&P 500. ...
Explore the top gainers and losers within the dow jones index in today's session.
Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Tue...
These S&P500 stocks are moving in today's session
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Tuesday as we examine the late...
Sector Update: Healthcare Stocks Fall Tuesday Afternoon
Healthcare stocks were lower Tuesday afternoon, with the NYSE Healthcare Index falling 1.1% and the
Here’s What’s Dragging Down the Dow
A decent day for the Dow has completely flipped on its head.
Johnson & Johnson's Upgraded Full-Year Outlook Misses Wall Street Views; Stock Declines
Johnson & Johnson (JNJ) raised its full-year outlook on Tuesday even though the upgraded midpoints m
Why Johnson & Johnson Stock Dropped Today
Johnson & Johnson beat earnings this morning. Then its stock price dropped.
J&J Takes a $5.5 Billion Talc Charge as MedTech Growth Slows From 7.7% to 2.5%
Johnson & Johnson (JNJ:NYSE) shares opened down about 4% on Tuesday, October 13, even though the company beat third-quarter estimates and raised i...
JPMorgan Chase, Goldman, Micron, J&J, UnitedHealth, Six Flags, Fermi, and More Stocks That Explain Today’s Market
JPMorgan Chase rises slightly as the bank generates $15.3 billion in net income in the third quarter, up 6% from a year earlier.
Johnson & Johnson Q3 2026 Earnings Call Summary
Moby summary of Johnson & Johnson's Q3 2026 earnings call
Johnson & Johnson: Keep Calm And Hold On
Johnson & Johnson is downgraded to a Hold, citing mixed fundamentals and regulatory headwinds. Read more on JNJ stock here.
Johnson & Johnson (JNJ) Q3 2026 Earnings Call Transcript
Johnson & Johnson (JNJ) Q3 2026 Earnings Call October 13, 2026 8:30 AM EDTCompany ParticipantsRyan Koors - Vice President of Investor RelationsJoa...
Discover which dow jones stocks are making waves on Tuesday.
Curious about the dow jones stocks that are in motion on Tuesday? Join us as we explore the top movers within the dow jones index during today's ...
Explore the top gainers and losers within the S&P500 index in today's session.
Stay informed about the performance of the S&P500 index in the middle of the day on Tuesday. Uncover the top gainers and losers in today's se...
Stock Market Midday, Oct. 13: Bank Earnings and Chip Pressure Drive Mixed Trading
Goldman Sachs gains on strong revenue while Johnson & Johnson stumbles on earnings miss, today, Oct. 13, 2026.
J&J’s medtech business slows again in Q3
For the second straight quarter, the cardiovascular unit experienced slower sales growth due to ongoing struggles in the Abiomed business.
Johnson & Johnson stock falls despite strong earnings as investors focus on medtech unit
Johnson & Johnson stock is tumbling even after the healthcare giant raised its forecast again for full-year earnings and revenue.
What Johnson & Johnson (JNJ) Said on Its Q3 Earnings Call
Johnson & Johnson (NYSE:JNJ) reported third-quarter 2026 worldwide sales of $25.4 billion, up 6% operationally from a year earlier, as growth in i...
Top Midday Stories: JPMorgan Shares Rise Despite Q3 Miss; J&J EPS Guidance Undershoots Estimates, Shares Fall
All three major US stock indexes were down in late-morning trading Tuesday, as the big banks kicked
Tremfya rescues J&J’s immunology sales to fuel strong Q3
Despite several products succumbing to generics and biosimilars, J&J raised its 2026 guidance.
Wall Street Lunch: Bank Earnings Nothing To Write Home About
JPMorgan misses earnings forecasts as big banks kick off reporting. UnitedHealth raises its full-year outlook for the third time. Fund managers pile i...
Johnson & Johnson Tops Q3 Estimates, Raises 2026 Outlook on Cancer Drug Strength (UPDATED)
Johnson & Johnson beats Q3 2026 earnings expectations with $25.39B in sales and raises its full-year revenue and profit guidance.
Domino's Drops on Sales Growth Miss; Bumble Goes Private | Stock Movers
On this episode of Stock Movers: - Domino's Pizza (DPZ) shares are lower after the restaurant chain reported total domestic stores comp sales gro...
Johnson & Johnson shares fall following earnings
Johnson & Johnson stock is tumbling despite the company raising its forecast again for full-year earnings and revenue.
Why this drug could become 'better than a $10B product': Johnson & Johnson CFO
Johnson & Johnson (JNJ) reported quarterly earnings on Tuesday and raised its full-year outlook. Johnson & Johnson CFO Joseph Wolk sits down w...
These S&P500 stocks are gapping in today's session
Curious about the S&P500 stocks that are gapping on Tuesday? Explore the gap up and gap down stocks in the S&P500 index during today's se...
QUICK SPARK: J&J Eyes Worst Day Since April 2025 with MedTech Miss
Johnson & Johnson beat third-quarter profit estimates and raised its 2026 forecast. After MedTech sales missed estimates, the stock still fell...
Johnson & Johnson raises 2026 guidance as quarterly sales climb
Johnson & Johnson (NYSE:JNJ), the healthcare group, raised its 2026 sales and earnings forecasts after third-quarter sales grew 6% on an operation...
Small-Business Optimism Dips in September
Small-Business Optimism Dips in September.
Big Banks out with earnings, J&J boosts outlook, Anthropic's latest AI warning
The 8:30 Hosts Julie Hyman, Jake Conley, and Pras Subramanian tackle the day's biggest news stories, including earnings out from major bank stock...
J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down
JNJ beats Q3 earnings estimates but misses sales expectations as MedTech lags. It raises its 2026 sales and earnings outlook.
JPMorgan Chase, Goldman Sachs, J&J, UnitedHealth, Six Flags, and More Stocks That Explain Today’s Market
JPMorgan Chase rises as the bank generates $15.3 billion in net income in the third quarter, up 6% from a year earlier.
Bank stocks rise on JPMorgan, Goldman earnings as chip stocks fall: AlphaCheck
Stocks were mixed on Tuesday as big banks kicked off earnings season.
Johnson & Johnson raises full-year outlook as momentum builds
Johnson & Johnson (JNJ) continues its hot streak as the pharmaceutical giant has raised its full-year outlook. The 8:30 Hosts, Julie Hyman, Jake C...
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transac...
'J&J Is Leaning Toward Spinning Out Its Hips-And-Knees Business' - The Wall Street Journal
https://www.wsj.com/business/earnings/j-j-is-leaning-toward-spinning-out-its-hips-and-knees-business-0de8d70d
Update: Johnson & Johnson Fiscal Q3 Adjusted Earnings Fall, Sales Increase; Fiscal 2026 Guidance Lifted
(Updates with CFO comments on planned spinoff of orthopedics unit in sixth paragraph, updates stock
$8,550 a Month and Zero Bonds: The Dividend Portfolio Retirees Are Building Instead
Skipping bonds in retirement sounds reckless, but a growing number of retirees are building six-figure income portfolios without a single Treasury not...
Mixed Pre-Markets Greet Fresh Q3 Earnings Reports
While JPM missed Q3 estimates, GS posted a strong quarter, with WFC somewhat in between.
How VYM’s $94.6B Dividend Kings Aided Portfolio Is Beating Treasuries
VYM's trailing yield sits well below what a 10-year Treasury pays today, yet the fund keeps attracting billions in new assets. The reason comes d...
Johnson & Johnson Q3 Earnings: Talc Resolution Offer Impacts Earnings, MedTech Slows Growth
Johnson & Johnson Q3 2026: revenue up 6%, but EPS fell, and shares slid 5% amid a $5.5B talc reserve. Click for this JNJ earnings update and see i...
Chip Stocks Slide as South Korea's KOSPI Plunges, J&J Sinks 6%: Stock Market Today
Chip stocks sold off after a 5% KOSPI plunge, with Micron and Applied Materials sinking, while J&J fell despite a guidance raise.
Health Bellwether J&J Slumps As Middle East Conflict Hampers Medtech Sales
Johnson & Johnson stock fell early Tuesday as the conflict in the Middle East weighted on medical device sales.
Johnson & Johnson Beats Third-Quarter Earnings Estimates and Raises 2026 Revenue and Profit Outlook
Johnson & Johnson (NYSE:JNJ) reported third-quarter 2026 earnings and revenue above Wall Street expectations on Tuesday, supported by growth in it...
Wall Street Analysts See Johnson & Johnson (JNJ) as a Buy: Should You Invest?
According to the average brokerage recommendation (ABR), one should invest in Johnson & Johnson (JNJ). It is debatable whether this highly sought-...
Compared to Estimates, Johnson & Johnson (JNJ) Q3 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended September 2026,...
5 Things to Know Before the Stock Market Opens on Tuesday
News of the day for Oct. 13, 2026
Johnson & Johnson 2026 Q3 - Results - Earnings Call Presentation
2026-10-13. The following slide deck was published by Johnson & Johnson in conjunction with their 2026 Q3 earnings call.
Earnings live updates: JPMorgan, Goldman Sachs stocks rise as big banks kick off Q3 earnings season
Big bank results kick off Q3 earnings season on Tuesday.
Tech Selloff Deepens as Bank Earnings Fuel Stock Market Rotation
The stock market is reacting to big bank earnings, Micron gets a warning from Elon Musk about Chinese memory chips, and more news to start your day.
Can a Spinoff Fix Johnson & Johnson’s Medtech Problem?
Johnson & Johnson says it is working to improve results in its medical-device business, where surgery revenue fell for the latest quarter.
Johnson & Johnson Hikes Earnings Guidance but Pharma Growth Masks a MedTech Stumble. Stock Falls.
Johnson & Johnson says it is working to improve results in its medical-device business, where surgery revenue fell for the latest quarter.
Johnson & Johnson (NYSE:JNJ) Q3 2026: In-Line Results and Raised Guidance Offset by MedTech Weakness
Johnson & Johnson Q3 2026 earnings in line, revenue slightly misses; MedTech lags, full-year guidance raised, shares fall premarket.
Bank Bank Earnings, Chip Drama Roil Wall Street Pre-Bell; Asia Mixed, Europe Up
Wall Street futures were mixed on the downside pre-bell Tuesday as traders digested big bank earning
4 Dividend Kings Retirees Can Buy and Hold Forever: Safe Income for the Next 60 Years
Four Dividend Kings have raised their payouts for decades, but a closer look at their cash flows reveals one payout hanging by a thread while another ...
Cyclicals Lead Sectors In Tuesday Trading As Health Care Trails
Four sectors are higher and seven are lower in Tuesday’s regular session, with cyclical sectors holding two of the top three positions. Materials si...
Johnson & Johnson beats estimates, raises 2026 guidance
Investing.com -- Johnson & Johnson (NYSE: JNJ) reported its latest quarterly results ahead of the open on Tuesday, exceeding analyst expectations.
Johnson & Johnson (JNJ) Q3 Earnings Surpass Estimates
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of +2.37% and -0.15%, respectively, for the quarter ended September 2026. Do the ...
Stock Market Today: Futures Mixed on Busy Earnings Day; Dow Lifted by UnitedHealth; Memory Stocks Weigh on Nasdaq
Stock futures were mixed Tuesday as several big banks and other notable companies reported quarterly results, with shares of memory chip makers fallin...
Johnson & Johnson: Q3 Earnings Snapshot
(AP) — Johnson & Johnson (JNJ) on Tuesday reported third-quarter profit of $210 million.On a per-share basis, the New Brunswick, New Jersey-base...
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026
NEW BRUNSWICK, N.J., October 13, 2026--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for ...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026
Company Announcement Net sales of DARZALEX® in the third quarter of 2026 totaled USD 4,239 millionGenmab receives royalties on worldwide net sales fr...
Transcript: Johnson & Johnson Q3 2026 Earnings Conference Call
Johnson & Johnson (NYSE:JNJ) held its third-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This ...
Johnson & Johnson (JNJ) Stock May Be 28% Undervalued As TREMFYA Data Impresses
Johnson & Johnson has delivered strong returns in recent years, and the question now is whether the cash the business can generate is enough to su...
Johnson & Johnson Says We Remain On Track For The Planned Separation Of Depuy Synthes By Mid 2027
-Conference Call.
Nasdaq Futures Sink, Dow Rises Premarket As AI Chip Stocks Wobble Ahead Of Big Bank Earnings: MU, SNDK, NVTS, NVDA, SPCX, ASTS, UNH, V Stocks In Focus
On Stocktwits, retail sentiment toward SPY and QQQ has remained ‘bullish’.
The Most Important Dividend Investing Lesson I've Ever Learned
Dividend Aristocrats and Dividend Kings are popular for good reason, but their impressive track records can create a dangerous false sense of security...
Johnson & Johnson CFO Joseph Wolk on the company’s Q3 results
Johnson & Johnson executive vice president and CFO Joseph Wolk joins 'Squawk Box' to discuss the company's quarterly earnings resul...
Earnings Scheduled For October 13, 2026
Companies Reporting Before The Bell • Unity Bancorp (NASDAQ:UNTY) is likely to report quarterly earnings at $1.55 per share on revenue of $35.60 mil...
Johnson & Johnson Raises FY2026 Adj EPS Guidance from $10.96-$11.11 to $11.05-$11.15 vs $11.08 Est; Raises FY2026 Sales Guidance from $100.800B-$101.400B to $101.000B-$101.400B vs $101.296B Est
Johnson & Johnson (NYSE:JNJ) raises FY2026 Adj EPS guidance from $10.96-$11.11 to $11.05-$11.15 vs $11.08 analyst estimate. Raises FY2026 sale...
South Korea's Kospi index sinks more than 7% on semiconductor share sell-off over AI boom worries
HONG KONG (AP) — South Korea’s benchmark Kospi index dropped more than 7% on Tuesday on a sell-off of chip shares, and Asian shares mostly decline...
Stock Market: Will S&P 500 Open Up or Down Today?
Will S&P 500 open higher? Polymarket odds dip to 37% as Wall Street faces a Nasdaq selloff, Q3 bank earnings and Trump's new energy po...
JPMorgan, Goldman Sachs and 3 Stocks to Watch Heading Into Tuesday
JPMorgan, J&J, Goldman Sachs, Wells Fargo and Citi are set to report quarterly earnings before Tuesday’s open; shares edge higher after-hour...
Earnings from banks and J&J and home sales data: What to Watch
Market Domination Overtime host Brooke DiPalma takes a closer look at the top stories for investors to watch on Tuesday, October 13, including earning...